Correlation Between Kura Oncology and Nuvectis Pharma
Can any of the company-specific risk be diversified away by investing in both Kura Oncology and Nuvectis Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kura Oncology and Nuvectis Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Kura Oncology and Nuvectis Pharma, you can compare the effects of market volatilities on Kura Oncology and Nuvectis Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kura Oncology with a short position of Nuvectis Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kura Oncology and Nuvectis Pharma.
Diversification Opportunities for Kura Oncology and Nuvectis Pharma
0.25 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Kura and Nuvectis is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Kura Oncology and Nuvectis Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nuvectis Pharma and Kura Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kura Oncology are associated (or correlated) with Nuvectis Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nuvectis Pharma has no effect on the direction of Kura Oncology i.e., Kura Oncology and Nuvectis Pharma go up and down completely randomly.
Pair Corralation between Kura Oncology and Nuvectis Pharma
Given the investment horizon of 90 days Kura Oncology is expected to under-perform the Nuvectis Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Kura Oncology is 1.6 times less risky than Nuvectis Pharma. The stock trades about -0.17 of its potential returns per unit of risk. The Nuvectis Pharma is currently generating about -0.05 of returns per unit of risk over similar time horizon. If you would invest 789.00 in Nuvectis Pharma on August 31, 2024 and sell it today you would lose (261.00) from holding Nuvectis Pharma or give up 33.08% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Kura Oncology vs. Nuvectis Pharma
Performance |
| Timeline |
| Kura Oncology |
| Nuvectis Pharma |
Kura Oncology and Nuvectis Pharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Kura Oncology and Nuvectis Pharma
The main advantage of trading using opposite Kura Oncology and Nuvectis Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kura Oncology position performs unexpectedly, Nuvectis Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nuvectis Pharma will offset losses from the drop in Nuvectis Pharma's long position.| Kura Oncology vs. Protagonist Therapeutics | Kura Oncology vs. Merus BV | Kura Oncology vs. Replimune Group | Kura Oncology vs. Kalvista Pharmaceuticals |
| Nuvectis Pharma vs. Replimune Group | Nuvectis Pharma vs. Lyra Therapeutics | Nuvectis Pharma vs. Kronos Bio | Nuvectis Pharma vs. Gossamer Bio |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Complementary Tools
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |